FM
SPRY icon

Foster & Motley’s ARS Pharmaceuticals SPRY Stock Holding History

Foster & Motley’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$119K Hold
14,780
– – 0.01% 394
2025
Q4 		$172K Hold
14,780
– – 0.01% 385
2025
Q3 		$149K Hold
14,780
– – 0.01% 392
2025
Q2 		$258K Hold
14,780
– – 0.01% 360
2025
Q1 		$186K Buy
+14,780
New +$178K 0.01% 374

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Foster & Motley's SPRY Position: Q1 2026 in Review

Foster & Motley held its ARS Pharmaceuticals (SPRY) position steady in Q1 2026 at 14,780 shares worth $119K. The position accounts for 0.01% of the portfolio, ranked #394.

Foster & Motley first reported a position in SPRY in Q1 2025 and has held it in 5 quarters since. The position peaked at $258K in Q2 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Foster & Motley held 14,780 shares of ARS Pharmaceuticals worth $119K as of Q1 2026.
  • Foster & Motley left its ARS Pharmaceuticals share count unchanged in Q1 2026.
  • ARS Pharmaceuticals made up 0.01% of Foster & Motley's portfolio in Q1 2026, its #394 holding.
  • Foster & Motley first reported a position in ARS Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Foster & Motley's ARS Pharmaceuticals position peaked at $258K in Q2 2025.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Foster & Motley's 13F filing for Q1 2026, filed 21 Apr 2026.